Explore By Subject Area   
Return Home
Menu

Lead Editorial

How Circulating Tumor DNA is Being Evaluated as a Potential Endpoint for Immuno-Oncology

How Circulating Tumor DNA is Being Evaluated as a Potential Endpoint for Immuno-Oncology

Jeff Allen, PhD, President and CEO of Friends of Cancer Research, discusses how the organization’s ctMoniTR project is evaluating the use of ctDNA as a potential endpoint, by aggregating data to provide a roadmap for future use in clinical trials.

Read More

Featured Editorial

Why Some People Respond to IO, and Others Don’t

Read More

What Immuno-Oncologists Need to Know About Radiopharmaceuticals

Read More

Key Skills and Career Moves on the Journey to Becoming a CEO, with Fred Hassan

Read More

Transforming Autoimmune Patient Outcomes with CAR T

Read More

More Related Content

Editorial

Practical Considerations of Response Assessment in Neuro-Oncology 2.0 for Clinical Trials

Practical Considerations of Response Assessment in Neuro-Oncology 2.0 for Clinical Trials

Sponsored
Unlocking Precision Medicine, Tumor Heterogeneity and Patient Monitoring with Advances in Imaging

Unlocking Precision Medicine, Tumor Heterogeneity and Patient Monitoring with Advances in Imaging
Developing a Molecule to Help Patients Respond to Immunotherapy

Developing a Molecule to Help Patients Respond to Immunotherapy
A New Approach to Cancer Vaccines, With a Focus on T Cells

A New Approach to Cancer Vaccines, With a Focus on T Cells
IO360º 2024 – Utilization of IO Agents in Adjuvant Disease and Update on Adjuvant Vaccine Studies

IO360º 2024 – Utilization of IO Agents in Adjuvant Disease and Update on Adjuvant Vaccine Studies
Providing IO Options for Breast Cancer Patients

Providing IO Options for Breast Cancer Patients
Dr Roy Baynes on Strategy Development for Keytruda

Dr Roy Baynes on Strategy Development for Keytruda
Embracing the Role of the Chief Medical Officer at Legend Biotech

Embracing the Role of the Chief Medical Officer at Legend Biotech
How Circular RNA is Enabling In Vivo CAR Delivery and Reducing Patient Treatment Burden

How Circular RNA is Enabling In Vivo CAR Delivery and Reducing Patient Treatment Burden
RNA Therapeutics for Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

RNA Therapeutics for Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer
Moffitt Cancer Center CEO Dr Patrick Hwu on CAR T, TILs and Tracking Patient Outcomes

Moffitt Cancer Center CEO Dr Patrick Hwu on CAR T, TILs and Tracking Patient Outcomes
The Role of Generative AI in Making Better Immuno-Oncology Therapeutics

The Role of Generative AI in Making Better Immuno-Oncology Therapeutics
Pushing IO and Cell Therapy Further at Astellas

Pushing IO and Cell Therapy Further at Astellas
​​​​​​​Reporting on the Latest Advancements and Data in IO: Immuno-Oncology 360° 2024 Recap

​​​​​​​Reporting on the Latest Advancements and Data in IO: Immuno-Oncology 360° 2024 Recap
When Immunotherapy Offers the Chance for Life and Family After Cancer Diagnosis

When Immunotherapy Offers the Chance for Life and Family After Cancer Diagnosis
Getting Cell Therapies into Solid Tumors and Avoiding Immune Suppression

Getting Cell Therapies into Solid Tumors and Avoiding Immune Suppression
The First-Time CEO Using a New Paradigm to Attack Metastatic Cancer

The First-Time CEO Using a New Paradigm to Attack Metastatic Cancer
The Biotech Analyst Helping Immuno-Oncology Investors Make Better Decisions

The Biotech Analyst Helping Immuno-Oncology Investors Make Better Decisions
How to Make Tumors More Targetable, Using the Tumor Microenvironment

How to Make Tumors More Targetable, Using the Tumor Microenvironment
Improving CAR T therapies with Better Patient Access at Novartis

Improving CAR T therapies with Better Patient Access at Novartis
Carl June and Daniel Chen on the Future of CAR-T, Cell Therapy, T-Cell Engagers and Synthetic Immunity

Carl June and Daniel Chen on the Future of CAR-T, Cell Therapy, T-Cell Engagers and Synthetic Immunity
Using Innate Immunity to Create a New Way of Going After Cancer

Using Innate Immunity to Create a New Way of Going After Cancer
Localizing Immuno-Oncology: The Right Therapy, to the Right Tumor

Localizing Immuno-Oncology: The Right Therapy, to the Right Tumor
The Regulatory Affairs Leader Helping to Advance Novel Therapies and Establish New Surrogate Endpoints

The Regulatory Affairs Leader Helping to Advance Novel Therapies and Establish New Surrogate Endpoints
Giving New Hope to Myeloma Patients and Working on the Next Generation of Cell Therapies

Giving New Hope to Myeloma Patients and Working on the Next Generation of Cell Therapies
Developing New Checkpoint Inhibitors for Patients and Finding Inspiration from Immunotherapy

Developing New Checkpoint Inhibitors for Patients and Finding Inspiration from Immunotherapy
Building a Biotech from a Technology That Turns Target Identification on its Head

Building a Biotech from a Technology That Turns Target Identification on its Head
Going from R&D to Commercial to Have a Different Impact on Patient Lives

Going from R&D to Commercial to Have a Different Impact on Patient Lives
Blocking GDF-15 to Conquer Immunosupression and Enhance Treatment Efficacy

Blocking GDF-15 to Conquer Immunosupression and Enhance Treatment Efficacy
Dr Carolyn Bertozzi Shares Her Award-Winning Work in IO and Her Hope for Greater Diversity in the Field

Dr Carolyn Bertozzi Shares Her Award-Winning Work in IO and Her Hope for Greater Diversity in the Field
Directing AstraZeneca's Oncology Strategies

Directing AstraZeneca's Oncology Strategies
UPenn's Dr Bruce Levine on Advancements in Cell Therapy Manufacturing

UPenn's Dr Bruce Levine on Advancements in Cell Therapy Manufacturing
How the NYU Genome Center is Making Better Cell Therapies

How the NYU Genome Center is Making Better Cell Therapies
Developing MSK's First Gene Transfer Clinic, Expediting Cell Therapy

Developing MSK's First Gene Transfer Clinic, Expediting Cell Therapy
MGH Cancer Center Breaks Down the T Cell to Better Understand Immuno-Oncology

MGH Cancer Center Breaks Down the T Cell to Better Understand Immuno-Oncology
New Approaches to Treat Brain Cancers Out of City of Hope

New Approaches to Treat Brain Cancers Out of City of Hope
Leading Immune Checkpoint Therapy Trials in NSCLC, at MD Anderson

Leading Immune Checkpoint Therapy Trials in NSCLC, at MD Anderson
Merck's Mission for More Effective Breast Cancer Immunotherapy Treatments

Merck's Mission for More Effective Breast Cancer Immunotherapy Treatments
BMS on Managing IO Operations and Sparking Joy for Science in Young People

BMS on Managing IO Operations and Sparking Joy for Science in Young People
Combining Natural Killer Cells and Synthetic Biology to Fight Solid Tumor Cancers

Combining Natural Killer Cells and Synthetic Biology to Fight Solid Tumor Cancers
Takeda’s Approach to Translational Medicine in Immuno-Oncology

Takeda’s Approach to Translational Medicine in Immuno-Oncology
Archive Highlight: How Genomics Is Advancing the Next Generation of IO at the Cleveland Clinic

Archive Highlight: How Genomics Is Advancing the Next Generation of IO at the Cleveland Clinic
Dr Arie Belldegrun on Staying Ahead of the Scientific Curve

Dr Arie Belldegrun on Staying Ahead of the Scientific Curve

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.